SBFM Q2 2025 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9M+1.2% YoY

Gross Profit

$3M36.4% margin

Operating Income

-$2M-21.8% margin

Net Income

-$2M-18.8% margin

EPS (Diluted)

$-7.80

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$32M

Total Liabilities

$6M

Stockholders' Equity

$26M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$9M	+1.2%
Gross Profit	$3M	$2M	+48.5%
Operating Income	-$2M	-$1M	-62.0%
Net Income	-$2M	-$494,000	-258.5%